The impact of serum visfatin, and resistin levels on insulin resistance in patients with polycystic ovary syndrome

  • Shatha Rouf Moustafa Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
  • Hussein Kadhem Al-Hakeim Department of Chemistry, Faculty of Science, University of Kufa, Kufa, Iraq.
Keywords: Insulin, Insulin resistance, Polycystic ovarian syndrome, Resistin, Visfatin


Background and objective: Women with polycystic ovary syndrome serve as a model to estimate the functions of insulin resistance and chronic hyperinsulinemia on serum level of insulin resistance markers. This study aimed to determine the association of the serum visfatin, resistin levels with insulin resistance in patients with polycystic ovary syndrome, and its correlations with various parameters.

Methods: This case-control study was performed at the College of Pharmacy, Hawler Medical University in the period between May 2017 and July 2018. It included 100 patients and 100 age matched healthy control group was also enrolled for comparing purposes.

Results: Patients had significantly elevated serum visfatin ( 2.46 vs. 1.08 ng/ml), resistin (3.87 vs. 2.46ng/ml), and insulin (17.22 vs. 8.1 µlU/ml) levels than controls. They also had significant elevations in insulin resistance (2.41 vs. 1.92) and β insulin function (94.45 vs. 86.98). There was no significant variation in insulin sensitivity (88.77 vs. 92.08).

Conclusion: There was an association between resistin, visfatin, and polycystic ovary syndrome-related insulin resistance. Many recent proteins are now considered as potential new markers of insulin resistance in polycystic ovary syndrome. There was a strong connection between visfatin and resistin with insulin resistance in polycystic ovary syndrome pathophysiology.


Amato MC, Vesco R, Vigneri E, Ciresi A, Giordano C. Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. J Endocrinol Invest 2015; 38(12):1319–26.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–9.

Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006; 20:293.

Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arq Bras Endocrinol Metabol 2014; 58(2):182–7.

Thomas S, Suresh S, Sudheesh M, Vijayakumar T. Association of insulin resistance with adipocytokinelevels in patients with metabolic syndrome. Indian J Clin Biochem 2015; 30(2):155–60.

Hamada M, Abe M, Miyake T, Kawasaki K, Tada F, Furukawa S, et al. B cell-activating factor controls the production of adipokines and induces insulin resistance. Obesity 2011; 19(10):1915–22.

Lewandowski KC, Szosland K, O'Callaghan C, Tan BK, Randeva HS, Lewinski A. Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Mol Genet Metab 2005; 85(1):61–9.

Ahmed MB, Ismail MI, Meki AR. Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients. Int J Health Sci 2015; 9(2):127–39.

Hug C, Lodish HF. Medicine. Visfatin: a new adipokine. Science 2005; 307(5708):366–7.

Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003; 18(9):1790–6.

Gul OO, Cander S, Gul B, Açıkgoz E, Sarandol E, Ersoy C. Evaluation of insulin resistance and plasma levels for visfatinand resistin in obese and non-obese patients with polycystic ovary syndrome. Eur Cytokine Netw 2015; 26(4):73–8.

Huma N, Patra SK, Binita G, Anju J, Chitra R. Study of Association of Leptin and Insulin Resistance Markers in Patients of PCOS. Indian J Clin Biochem 2016; 31(1):104–7.

Vejrazkova D, Lischkova O, Vankova M, Stanicka S, Vrbikova J, Lukasova P, et al. Distinct response of fat and gastrointestinal tissue to glucose in gestational diabetes mellitus and polycystic ovary syndrome. Physiol Res 2017; 66(2):283–92.

Bertha P, Irawan Y, Muchtaruddin M, Andi W. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Ther Adv Endocrinol Metab 2011; 2(6):235–45.

Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011; 96(2):E304–11.

Jin JK, Young MC, Min AH, Min JK, Soo JC, Sun MK, et al. Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls. Obstet Gynecol Sci 2018; 61(2):253–60.

Mendonça HC, Montenegro RM, Foss MC, Silva De Sa MF, Ferriani RA. Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome. Braz J Med Biol Res 2004; 37(5):729–36.

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307(5708):426–30.

Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocełak P, Semik-Grabarczyk E, Holecki M, et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56(8):1131–4.

Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54(10):2911–6.

Sun Y, Wu Z, Wei L, Liu C, Zhu S, Tang S. High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis. Gynecol Endocrinol 2015; 31(10):808–14.

Seow KM, Hwang JL, Wang PH, Ho LT, Juan CC. Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome. Hum Reprod 2011; 26(10):2869–73.

Wang Y, Xie X, Zhu W. Serum adiponectin and resistin Levels in patients with polycystic ovarian syndrome and their clinical implications. J Huazhong Univ Sci Technol Med Sci 2010; 30(5):638–42.

Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obesity Res 2003; 11(8):997–1001.

Chen X, Jia X, Qiao J, Guan Y, Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol 2013; 50(2):R21–37.

Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res 2013; 40:40–50.

Yilmaz M, Bukan N, Demirci H, Oztürk C, Kan E, Ayvaz G, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25(4):246–52.

Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000; 15(1):24–8.

How to Cite
Moustafa, S., & Al-Hakeim, H. (2020). The impact of serum visfatin, and resistin levels on insulin resistance in patients with polycystic ovary syndrome. Zanco Journal of Medical Sciences (Zanco J Med Sci), 24(1), 80-88.
Original Articles